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Although peritoneal dissemination of cancer cells often
occurs at the advanced stages of pancreatic, gastric or
ovarian cancers, no effective therapy has been established.
Cationic lipid-mediated gene transfer into peritoneal dissemi-
nation may offer a prospect of safe therapies, but vector
improvements are needed with regard to the efficiency and
specificity of the gene transfer. In this study, the intraperi-
toneal injection of plasmid DNA:polyethylenimine (PEI) com-
plexes into mice was evaluated as a gene delivery system
for the peritoneal disseminations. The luciferase and b-
galactosidase genes were used as marker genes. PEI was
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Introduction
Adenocarcinoma of the pancreas is one of the most diffi-
cult cancers to treat at present.1 By the time of diagnosis,
most patients have extensive metastasis, primarily to the
liver, peritoneum and lymph system. Peritoneal dissemi-
nation is also one of the most frequent modes of recur-
rence after surgery.1,2 Moreover, it is often associated
with intractable ascites leading to substantial impairment
of the patient’s quality of life. Yet, no effective therapy
has so far been established to alleviate this devastating
and often fatal end-stage condition.3,4 Thus, there is an
urgent need to develop a new modality of treatment for
peritoneal dissemination of pancreatic cancer. Gene ther-
apy strategies may provide therapeutic benefits with a
more favorable risk–benefit ratio than the current con-
ventional treatments.
Many groups are investigating the gene therapy for
peritoneal metastasis; several reports demonstrated the
efficacy of suicide gene therapy with the gene transfer of
herpes simplex virus thymidine kinase (HSVtk) gene and
cytosine deaminase gene using various vectors.5–8 As
regards an apoptosis-inducing gene therapy, the treat-
ment of adenovirus encoding p53 gene effectively sup-
pressed the growth of peritoneal tumors in ovarian can-
Correspondence: T Yoshida, Genetics Division, National Cancer Center
Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104, Japan
Received 29 June 2000; accepted 15 January 2001
more efficient than the cationic lipids examined in this study
in vivo, and the transgene was preferentially expressed in
the tumors. Although PCR analysis showed that the injected
DNA was delivered to various organs, the distributed DNA
became undetectable by 6 months after the gene transfer.
Blood chemistry and histological analysis showed no sig-
nificant toxicity in the injected mice. This study demonstrated
that the intraperitoneal injection of DNA:PEI is a promising
delivery method to transduce a gene into disseminated can-
cer nodules in the peritoneal cavity. Gene Therapy (2001)
8, 508–514.
cer model,9 and the administration of BAX-expressing
adenovirus was capable of eradicating .99% of ovarian
tumor implants.10 A phase I trial suggested that aden-
ovirus-mediated gene therapy using anti-erbB2-directed
intrabody is feasible in the human ovarian cancer.11 As
an anti-angiogenesis strategy, intraperitoneal transduc-
tion of a soluble Flt-1 gene using HVJ-liposome sup-
pressed peritoneal metastasis in mice.12 Tanaka et al13
reported the immune gene therapy by in vivo transfer of
IL-6 gene using adenovirus vector in SCID-PBL/hu mice.
We have been developing lipofection as a method for in
vivo delivery of therapeutic genes such as antisense K-ras
and HSVtk gene into peritoneal dissemination of pancre-
atic cancer.14,15 DNA-mediated transfection has major
advantages in that it raises none of the concerns of viral
vectors for human gene therapy; it is not associated with
the possibility of generating a replication competent
virus, there is no acute toxicity or immune reaction such
as those experienced for adenovirus vectors, it is more
stable in vivo than retroviral vectors, and multiple injec-
tion will be less problematic than a virus-based gene
transfer.16,17 However, nonviral gene delivery techniques
do not compare favorably with viral vectors on the basis
of efficiency of gene transfer to a cell. More efficient vec-
tors are needed to improve the low gene transfer
efficiency.
Among nonviral vectors, two main classes of molecules
have been used: (1) cationic lipids such as N[1-(2,3-
dioleyloxy)propyl]-n,n,n-trimethylammonium chloride
(DOTMA), dioctadecylamidoglycylspermine (DOGS) or
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onium bromide (DMRIE);18–20 and (2) polymeric DNA-
binding cations such as poly-l-lysine, protamine, cat-
ionized albumin, and more recently, polyethylenimine
(PEI).21,22 PEI is the organic macromolecule with the high-
est cationic-charge-density potential; every third atom is
an amino nitrogen that can be protonated, which makes
the polymeric network an effective ‘proton sponge’ at vir-
tually any pH.21 In this study, we first compared the gene
transfection efficiency between a linear form of PEI and
several widely used cationic liposomes in vitro and found
that PEI shows the best overall transfection efficiency in
pancreatic cancer cells. The data prompted us to investi-
gate whether an in vivo gene transfer into intraperitone-
ally disseminated tumors could be effectively achieved
by PEI. This study demonstrated that the direct intraperi-
toneal injection of DNA:PEI complexes is an efficient and
safe method for in vivo gene transfer into intraperi-
toneal tumors.
Results
Comparison of gene transfer efficiency between PEI
and cationic liposomes
To compare the relative efficiencies of PEI and various
cationic liposomes in transfecting pancreatic cancer cell
lines, we evaluated the expression of the reporter gene,
luciferase. The PEI exhibited higher luciferase activity
than other cationic liposomes in three of four cell lines
(Figure 1a). In Panc-1 cells, DMRIE/cholesterol showed
Figure 1 Comparison of gene transfer efficiency between PEI and cationic
liposomes. (a) The luciferase activity following transfection of pancreatic
cancer cell lines in vitro. Two micrograms of pCAG-luci was transfected
using PEI or several cationic liposomes. The assays (performed in
triplicate) were repeated a minimum of two times and average numbers
plotted with standard deviation. Results were expressed as light unit per
mg of cell protein. (b) Expression of luciferase in tumors on the mesentery
after the intraperitoneal injection of DNA:cationic vector complexes.
DNA:cationic vector complexes were injected three times into the perito-
neal cavity of three mice with peritoneal dissemination.
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the highest luciferase expression and approximately the
same activity was observed with PEI and DOTMA/
DOPE. The in vivo gene transfer into intraperitoneally
disseminated tumors was then examined after intraperi-
toneal injection of plasmid DNA:PEI complexes. We com-
pared PEI with DMRIE/cholesterol or DOGS, because
DMRIE/cholesterol exhibited a higher transfection
efficiency among the cationic liposomes in vitro (Figure
1a) and gene therapy experiments using DOGS were suc-
cessful in mouse models of pancreatic peritoneal tumors,
as previously reported.14,15 AsPC-1 cells were trans-
planted to the peritoneal cavity of nude mice, and pCAG-
luci was injected as a complex, either with PEI,
DMRIE/cholesterol or DOGS. As shown in Figure 1b, PEI
was more efficient than cationic lipids in transducing the
luciferase gene into the peritoneal dissemination of mice.
Gene transfer into intraperitoneally disseminated tumors
using DNA:PEI complexes
As shown in Figure 2a, repeated injections of pCAG-luci
DNA:PEI complexes increased the magnitude of trans-
gene expression in tumors on the mesentery. Three injec-
tions increased the luciferase expression more than 10-
fold compared with that obtained using a single injection.
Comparison of luciferase expression between pCAG-luci
DNA:PEI complex and the naked plasmid pCAG-luci
DNA demonstrated that PEI enhanced the gene transfer
efficiency approximately 100–1000-fold compared with
the naked plasmid, confirming that PEI is practically
essential to mediate gene transfer (Figure 2b). To define
the tissue distribution of the gene expression, luciferase
activity was analyzed in many organs after the intraperi-
toneal injection of pCAG-luci DNA:PEI complexes for a
total of three times. High luciferase activities (1.2–1.4 ×
106 RLU/mg protein) were observed only in tumors on
the mesentery and pancreas, and low activities were
detected in some organs such as spleen, stomach, and
skeletal muscle. Other organs such as the brain, lung,
heart, liver, kidney, testis, and small intestine did not
show any luciferase activity (Figure 2b, left). The lucifer-
ase activity was maximal at day 1, and it was detectable
up to day 7 in tumors on the mesentery. In the spleen, the
luciferase activity was detected up to day 4 (Figure 2c).
To analyze the distribution of gene delivery in the
tissue further, pCAG-lacZ DNA:PEI complexes were
injected into murine peritoneal cavity, and b-galacto-
sidase expression was examined in tumors on the mesen-
tery and other organs. Blue-stained cells were observed
only in tumors on the mesentery (Figure 2d), but not in
other normal organs including the peritoneum and renal
capsule. We think the discrepancy between luciferase
assay and X-gal staining is explained by the low
sensitivity of X-gal.15
Peritoneal barrier against PEI-mediated gene transfer
We tried to understand a part of the mechanisms for
tumor-preferential expression of a transgene following
intraperitoneal injection of DNA:PEI complexes. Unlike
the tumor nodules disseminated on the peritoneum, nor-
mal organs in the peritoneal cavity are covered by the
peritoneum and underlying connective tissue (Figure 3a,
arrow), which may constitute a barrier against the entry
of DNA:PEI complexes through the surface of organs. To
test this premise, the peritoneum and an underlying
fibrous layer (renal capsule) covering the right kidney
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Figure 2 Luciferase expression in the organs after the intraperitoneal injection of DNA:PEI complexes. After intraperitoneal transplantation of AsPC-
1 cells, Balb/c nude mice were intraperitoneally injected with pCAG-luci complexed with PEI. Results were expressed as light unit per mg of tissue
protein. (a) Dose dependency of transgene expression in tumors on the mesentery. The pCAG-luci:PEI complexes were injected into the peritoneal cavity
either once, or two or three times (n = 3) at 12 h intervals. For each group, the luciferase activity of tumors on the mesentery was assayed 24 h after
the last injection. (b) Tissue distribution of a transgene expression. (Left) pCAG-luci:PEI complexes were injected three times into the peritoneal cavity
of five mice. (Right) pCAG-luci plasmids were injected three times into the peritoneal cavity of five mice. Mesenteric T., tumors on the mesentery;
pancreatic T., tumors on the pancreas. (c) Time course of luciferase expression. After three injections of pCAG-luci:PEI complexes, the expression levels
of the luciferase gene were assayed 1, 4, 7 and 11 days later in the spleen and in tumors on the mesentery. Black box, tumors on the mesentery (n =
3); hatched box, the spleen (n = 3). (d) Histochemical demonstration of the b-galactosidase activity in intraperitoneal tumors. After intraperitoneal
transplantation of AsPC-1 cells, a Balb/c nude mouse was intraperitoneally injected with pCAG-lacZ complexed with PEI 3 times. Arrows: X-gal-
positive, blue-stained cell. Counter staining by hematoxylin and eosin (×100).
were surgically peeled off (Figure 3b), and then pCAG-
luci:PEI complexes were instilled directly on to the sur-
face of the renal parenchyma. As a control, the same in
vivo gene transfer was attempted on the left kidney
(Figure 3c, 1st column) with an intact surface. No lucifer-
ase expression was detected in the left kidney, whereas
the right kidney showed a significant luciferase activity
(2.4 × 103 RLU/mg protein) (Figure 3c, 2nd column).
Next, the transgene expression within the cells of the
peritoneal lining was assayed. The intraperitoneal injec-
tion of pCAG-luci:PEI complexes produced a relatively
high luciferase activity (1.0 × 105 RLU/mg protein) in the
peritoneum and an underlying fibrous layer (renal
capsule) covering the kidney (Figure 3c, 3rd column).
Although the gene transfer into the kidney with or with-
out peritoneal barrier was examined by the instillation of
pCAG-lacZ DNA:PEI complexes, blue-stained cells were
not detected in the kidney parenchyma and capsule.
Persistence of distributed DNA and its toxicity
To determine organ distribution of injected DNA and
time course of its clearance, the presence of DNA was
examined in various organs by PCR analysis after the
intraperitoneal injection of DNA:PEI complexes. The sen-
sitivity of the PCR analysis was estimated to be about
one copy per 102–103 genomes. The PCR analysis of DNA
from various organs showed that the injected DNA was
present in all organs 7 days after the injection. The band
intensities of the luciferase gene decreased in all organs
except for the brain 3 months later, and the transgene was
detectable in none of the organs 6 months later (Figure
4). Furthermore, to characterize the potential toxicity of
intraperitoneally injected DNA:PEI, 100 mg of pCAG-luci
complexed with PEI (N/P = 7) was intraperitoneally
injected into Balb/c mice (n = 5) three times at 12-h inter-
vals. Animals were killed 1, 3 and 10 days after the injec-
tion to evaluate blood chemistry and histology of major
PEI-mediated gene transfer into peritoneal dissemination
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Figure 3 Gene transfer into the kidney by instillation of DNA:PEI com-
plexes. (a) Representative sections of the pancreas and tumors on the pan-
creas. The pancreas (left) and tumor nodules on the pancreas (right) were
stained with hematoxylin and eosin (×100). Arrow: peritoneum. (b,
c) Gene transfer into the renal parenchyma by the instillation of DNA:PEI
complexes. The kidneys were stained with hematoxylin and eosin (arrow)
(b) (×200). The peritoneum and underlying fibrous component (capsule)
on the right kidney was peeled off (b, right), then 50 mg of pCAG-luci
complexed with PEI (N/P = 7) were instilled on to the kidney (c, 2nd
column). As a control, the same dose of pCAG-luci:PEI complexes was
also instilled on to the left kidney with those tissues (b, left; c, 1st column)
at the same time. After incubation of 30 min, the abdomen was closed,
and 24 h later the luciferase activity was assayed (c; n = 5). On the other
hand, 100 mg of pCAG-luci complexed with PEI was intraperitoneally
injected, and 24 h later the peritoneum and an underlying fibrous layer
(renal capsule) covering the kidney were assayed for luciferase activity (c,
3rd column; n = 5).
organs. No significant toxicity was observed with blood
chemistry (Table 1), hematoxylin- and eosin-stained sec-
tions and monitoring animal body weights (data not
shown).
Discussion
PEI is one of the polycations that have been used success-
fully to transduce genes into living cells. Many groups
have been investigating the in vivo gene transfer of DNA:
PEI complexes by various routes. It was reported that
widespread expression was obtained in neurons and glia
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after the direct injection into the brain or intraventricular
injection of DNA:PEI.22,23 DNA:PEI complexes effectively
transduced pseudocystic tumors when they are injected
in the cyst.24 Intravenous injection led to efficient gene
transfer into the normal lung epithelial cells and hepato-
cytes,24–28 but subcutaneous tumors as well as lung met-
astases were not transfected by systemic injection.23 To
the best of our knowledge, this paper is a first report eval-
uating PEI as a gene delivery system into peritoneal dis-
semination by intraperitoneal injection. This study
showed that the intraperitoneal injection of DNA:PEI
complexes achieves a tumor-preferential transgene
expression (Figure 2b and d).
Cationic liposomes have also been reported to trans-
duce a gene into intraperitoneal tumors in a tumor-pref-
erential manner, but the mechanism for this tumor target-
ability is not elucidated.15,29,30 The DNA:polycation
complexes might enter the lymphatics, then the blood cir-
culation, to be conveyed to various organs.31 Another
possible route of gene transfer is the direct entry of the
DNA:PEI complexes to the organ parenchyma through
its surface. The organs in the peritoneal cavity are nor-
mally covered with the peritoneum and subperitoneal
connective tissue, whereas the tumor nodules dissemi-
nated over the peritoneal surfaces are devoid of such
coverings, since the interaction of cancer cells with the
peritoneum induces disruption and exfoliation of the
mesothelial cells in the early process of peritonal metasta-
sis.32,33 The peritoneum and underlying fibrous compo-
nent may act as a barrier against the entry of DNA:PEI
complexes through the surface of organs. Interestingly,
relatively high luciferase activity was detected within the
cells of the peritoneum and underlying fibrous layer
(renal capsule), and a significant luciferase activity was
observed in the kidney parenchyma without the perito-
neal barrier. It appears that the peritoneal lining captures
the plasmid DNA:PEI complexes and prevents the spread
of the gene transfer into the underlying organ paren-
chyma. The kidney with peritoneal barrier showed no
luciferase activity, regardless of the effective gene trans-
fer into renal coverings. This may be explained by the
large volume ratio of kidney parenchyma to peritoneal
barrier, which means many more untransduced cells in
the organ core than transduced cells in the peritoneal
lining. An additional element which may account for the
apparent tumor-preference is that the transduced gene is
more readily expressed in rapidly proliferating cells such
as cancer cells than in normal cells with low mitogenic
activity.30,34,35 Since transfected DNA is probably trans-
ported inefficiently through the nuclear membrane dur-
ing interphase, it is likely that the breakdown of the
nuclear membrane during mitosis is crucial to efficient
entrance of the transfected DNA into the nucleus.36,37
Issues pertaining to the toxicity, kinetics and biodistri-
bution of DNA:PEI complexes need to be addressed.
Concern has been raised regarding the inadvertent intro-
duction of DNA into normal cells. Consistent with our
previous study with a liposome DOGS,14 PCR analysis
showed that the intraperitoneally injected DNA was
delivered to various organs. However, the luciferase
assay showed faint or no expression of a gene in normal
organs irrespective of the presence of plasmid DNA. Our
previous RT-PCR analysis to detect a transgene
expression revealed similar results.15 Thus, it is plausible
that DNA detected by PCR analysis might be the par-
PEI-mediated gene transfer into peritoneal dissemination
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Figure 4 Organ distribution of injected DNA and time course of its clearance after intraperitoneal injection of DNA:PEI. The plasmid DNA complexed
with PEI was intraperitonelly injected into Balb/c mice. The genomic DNA was analyzed by PCR for luciferase transgene or b-actin (marked) from
various organs (the brain, lung, heart, liver, pancreas, spleen, kidney, testis, stomach, small intestine, skeletal muscle, bone marrow, tumors on the
pancreas and the mesentery) 7 days (upper), 3 months (middle) and 6 months (lower) later. Positive control, pGL3 control plasmid; negative control,
no DNA.
Table 1 Evaluation of selected blood chemistries after intraperitoneal injection
PBS DNA:PEI
1 day 3 day 10 day
T. protein (mg/ml) 4.95 ± 0.42 4.68 ± 0.22 4.77 ± 0.36 4.92 ± 0.19
Albumin (mg/ml) 2.95 ± 0.13 2.93 ± 0.10 2.88 ± 0.12 3.20 ± 0.06
T. bilirubin (mg/ml) 0.60 ± 0.56 0.28 ± 0.26 0.40 ± 0.32 0.43 ± 0.42
BUN (mg/dl) 15.3 ± 0.45 15.7 ± 1.88 17.9 ± 1.35 21.8 ± 1.98
Creatinine (mg/ml) 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0
GOT (IU/I) 101.8 ± 74.1 114.2 ± 79.77 108.3 ± 56.08 55.5 ± 9.09
GPT (IU/I) 40.0 ± 4.00 35.8 ± 7.27 31.3 ± 8.21 34.0 ± 9.72
LDH (IU/I) 989.0 ± 742.5 522.8 ± 222.2 758.2 ± 315.4 648.3 ± 402.0
ALP (IU/I) 263.0 ± 57.2 227.8 ± 31.9 263.3 ± 21.0 336.5 ± 31.7
Blood chemistry values were analyzed (SRL, Tokyo, Japan), and mean values and standard deviations are shown for five mice in each
group 1, 3 and 10 days after the injection of plasmid DNA:PEI complexes. Control is PBS-injected mice (n = 8).
tially degraded fragments of plasmid or DNA attached
to the surface of organs. Moreover, the injected DNA was
no longer evident up to 6 months after injection, and no
significant abnormality was observed in blood chemistry
and histological sections of major organs. Because of the
efficient tumor-preferential expression and the lack of
toxicity, the intraperitoneal injection of DNA:PEI com-
plexes is expected to play an important role in future
treatment of peritoneal dissemination.
Materials and methods
Plasmid
The firefly luciferase gene and b-galactosidase gene were
used as reporter genes to monitor the result of gene trans-
fer. The luciferase expression plasmid (pCAG-luci) and
b-galactosidase expression plasmid (pCAG-lacZ) were
constructed by subcloning Photinus pyralis luciferase or E.
coli b-galactosidase cDNA to pCAGGS, respectively. The
PEI-mediated gene transfer into peritoneal dissemination
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promoter, which consists of the cytomegalovirus immedi-
ate–early enhancer sequence and the chicken b-
actin/rabbit b-globin hybrid promoter.38,39
Cells
AsPC-1, MIAPaCa-2 and Panc-1, human pancreatic can-
cer cell lines, were obtained from the American Tissue
Culture Collection (Bethesday, MD, USA). PGHAM-1, a
hamster pancreatic cancer cell line, was a gift from Dr
E Uchida (Nippon Medical School, Tokyo, Japan).40 All
pancreatic cancer cell lines were grown in RPMI-1640
medium (GIBCO BRL, Gaithersburg, MD, USA) sup-
plemented with 10% fetal bovine serum and antibiotics.
PEI
A linear form of polyethylenimine (PEI) of molecular
weight 22 kDa was synthesized by acid hydrolysis of 50
kDa poly (2-ethyl-2-oxazoline)s (Sigma-Aldrich, St Louis,
MO, USA). The ultimate elementary analysis showed that
the composition of synthesized PEI was C (%): 55.36, H
(%): 11.63, N (%): 31.37, which was almost the same for
the calculated composition (C: 55.81, H: 11.63, N: 32.56).
Assay for luciferase activity in vitro
Twenty-four hours before transfection, cells were seeded
at 2 × 105 cells per well in a six-well plate, and each well
received 2 mg of pCAG-luci. Transfection with N[1-(2, 3-
dioleyloxy)propyl]-n,n,n-trimethylammonium chloride
(DOTMA)/dioleoyl phoaphatidylethenolamine (DOPE)
(Lipofectin; GIBCO BRL), 2, 3-dioleyloxy-N-[2(sperm-
inecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium
trifluoroacetate (DOSPA)/DOPE (LiopfectAMINE; GIBCO
BRL), or 1, 2-dimyristyloxypropyl-3-dimethyl-hydroxye-
thyl ammonium bromide (DMRIE)/cholesterol (DMRIE-
C; GIBCO BRL) and dioctadecylamidoglycylspermine
(DOGS) (Transfectam; BioSepra, Marlborough, MA,
USA) were set up following optimal conditions sug-
gested by the manufacturers’ protocols. Since the trans-
fection efficiency of DNA:PEI complexes was maximal at
6.75 to 9 equivalents of PEI nitrogen per DNA phosphate
(N/P) (data not shown), we used 9 N/P in the in vitro
gene transfer. Twenty-four hours after transfection, cells
were lysed with 100 ml of cell lysis buffer (25 mm Tris-
phosphate, pH 7.8, 2 mm DTT, 2 mm EDTA, 10% glycerol,
1% Triton-X) and incubated at room temperature for 20
min. Three microliters of cell lysate was mixed with 100
ml of Luciferase Assay Reagent (PicaGene; Toyo Ink,
Tokyo, Japan), and the light unit of the luciferase activity
was measured using a luminometer (MiniLumat LB 9506;
EG&G Berthold, Vilvoorde, Belgium).
In vivo gene transfer into peritoneal dissemination
A linear form of polyethylenimine, and cationic lipo-
somes such as DMRIE-C or DOGS, were used as in vivo
transfection agents. Twenty-one days after the transplan-
tation of 1 × 106 AsPC-1 cells into the peritoneal cavity of
male Balb/c nude mice (Charles River Japan, Kanagawa,
Japan), the multiple peritoneal nodules about 2–3 mm in
diameter were formed. The mice were then intraperitone-
ally injected with the pCAG-luci or pCAG-lacZ com-
plexed with PEI, DOGS or DMRIE/cholesterol. For com-
plex formation, the following amounts of each vector
were used: for PEI transfection solution, 100 mg of plas-
mid was diluted in 300 ml of 5% glucose solution, and
Gene Therapy
the 2.1 mmol of a linear form of PEI (7 N/P) was diluted
in 300 ml of 5% glucose solution, and then the PEI sol-
ution was added to the plasmid solution; for DOGS trans-
fection solution, 100 mg of plasmid was diluted in 300 ml
of a 0.15 m NaCl solution, and the 400 nmol of DOGS
ethanolic solution was diluted in 350 ml of 0.15 m NaCl
solution, and then the DOGS solution was added to the
plasmid solution; for DMRIE/cholesterol transfection sol-
ution, 100 mg of plasmid was diluted in 300 ml of 10 mm
phosphate buffered saline (PBS), and 490 nmol of
DMRIE/cholesterol was added to the plasmid solution.
After 10 min, the resulting mixture was injected into the
intraperitoneal cavity. The mice were killed 24 h after the
last injection, and tissue samples were obtained from
tumor nodules on the pancreas and mesentery, and from
various normal organs (brain, heart, lung, liver, spleen,
pancreas, kidney, stomach, intestine, testis, muscle and
bone marrow).
Assay for luciferase activity in vivo
The frozen tissues were pulverized using liquid nitrogen,
an equal volume of tissue lysis buffer (125 mm Tris-phos-
phate, pH 7.8, 10 mm DTT, 10 mm EDTA, 50% glycerol,
5% Triton-X, 0.2 mm phenylmethylsulfonyl fluoride, 1
mg/ml aprotinin, 1 mg/ml leupeptin) was added, and
incubated on ice for 20 min. Twenty microliters of super-
natants was mixed with 100 ml of Luciferase Assay
Reagent (PicaGene), and the light unit of the luciferase
activity was assayed using a luminometer (MiniLumat
LB 9506). We calculated the mean value plus two stan-
dard deviations of each organ and tumor in untreated
mice as background values (n = 5), and then subtracted
background values from each luciferase value of samples
in DNA:PEI-injected mice. It was confirmed that the
tissue extract of various organs does not inhibit the
activity of luciferase enzyme (data not shown).
Assay for b-galactosidase in vivo
After intraperitoneal transplantation of AsPC-1 cells, a
Balb/c nude mouse was intraperitoneally injected with
100 mg of pCAG-lacZ complexed with PEI three times.
Forty-eight hours later, tumors in the mesentery were
fixed with 0.25% glutaraldehyde, and developed in a sub-
strate solution [5 mm K3Fe(CN)6, 5 mm K4(CN)6, 2 mm
MgCl2, and 1 mg/ml X-gal] at 37°C for 16 h.
PCR analysis of the injected DNA
PCR analysis was performed to evaluate the organ distri-
bution of intraperitoneally injected DNA and the time
course of its clearance. One hundred micrograms of
luciferase expression plasmid (pBL3 control vector; Pro-
mega, Madison, WI, USA) complexed with 2.1 mmol of
PEI was injected into Balb/c mice (Charles River Japan)
for a total of three times at 12-h intervals. The genomic
DNA was extracted from tumors and various normal
organs 7 days, 3 months and 6 months after the injection.
The 0.1 mg of DNA was subjected to PCR analysis using
two primers specific to the luciferase specific primers
(Luci-L, 59-GCGCCATTCTATCCGCTGGA-39; Luci-R, 59-
CTATCGAAGGACTCTGGCAC-39), which should yield
a 530-bp fragment. We performed PCR for 30 cycles at
94°C for 1 min, 60°C for 30 s, and 72°C for 2 min, and
the PCR products were electrophoresed on a 2.0%
agarose gel.
PEI-mediated gene transfer into peritoneal dissemination
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